|Bid||88.27 x 1100|
|Ask||88.28 x 1200|
|Day's Range||87.72 - 88.96|
|52 Week Range||57.17 - 88.96|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||33.41|
|Forward Dividend & Yield||2.92 (3.40%)|
|Ex-Dividend Date||Dec 14, 2022|
|1y Target Est||N/A|
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it. Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price. On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being.
Biotech giant Gilead Sciences (NASDAQ: GILD) is a member of this elite club, having seen its shares rise by 15% year to date. Let's consider two reasons why Gilead Sciences is worth serious consideration heading into the new year. Gilead Sciences' most important unit by some margin remains its HIV business.